Last November, I posted this note - re a fatty liver research project being funded by EMV - on the 'Emvision Research Notes' thread:
Electromagnetic Scanner for Hepatic Steatosis Detection, Classification and Monitoring (2021–2022)
Grant type:
EMvision Medical Devices Ltd
Researchers:
Funded by:
Professor Amin Abbosh
Professor
School of Information Technology and Electrical Engineering
Faculty of Engineering, Architecture and Information Technology
Dr Sasan Ahdi Rezaeieh
UQ Amplify Lecturer
School of Information Technology and Electrical Engineering
Faculty of Engineering, Architecture and Information Technology
EMvision Medical Devices Ltd
Given some exciting research status news out of this UQ/EMV partnership this week, I think this project warrants a separate thread.
The research update is authored by the inventor of EMV's tech, Professor Amin Abbosh and includes EMV's Algorithm Engineer, Mojtaba Khosravi-Farsani, on the team.
Fatty Liver Disease is huge - with 25% of the US population affected.
Based on the interim results and comparisons with Ultrasound and CT - see Conclusion below - the early detection of FLD via this electro-magnetic imaging could be a potential game changer:
VI. CONCLUSION
An effective permittivity estimation method, applicable to a multilayer and heterogeneous medium, such as the human torso, is proposed. Unlike previous techniques, the proposed method does not require any training process or large number of antennas around the domain. It can estimate the dispersive effective permittivity of each side of the torso and find the left/right contrast in permittivity.
The method can differentiate steatotic livers from healthy ones by their higher permittivity contrast. Additionally, the method is robust to different body structures and small errors in antenna positioning.
Its capability for clinical application is also verified via human tests.
Unlike, US and CT devices which cannot detect mild HS stage with less than 33% diffused fat, the proposed method is able to detect mild steatotic livers with only 15% diffused fat
https://www.researchgate.net/public...Contrast_in_Effective_Dispersive_Permittivity
- Forums
- ASX - By Stock
- EMV
- Hepatic Steatosis (Fatty Liver Disease)
Hepatic Steatosis (Fatty Liver Disease)
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EMV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.91 |
Change
-0.040(2.05%) |
Mkt cap ! $163.1M |
Open | High | Low | Value | Volume |
$1.95 | $1.95 | $1.91 | $36.28K | 18.81K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 11031 | $1.91 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.98 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 11031 | 1.910 |
2 | 983 | 1.880 |
1 | 200 | 1.850 |
1 | 4000 | 1.830 |
1 | 27000 | 1.810 |
Price($) | Vol. | No. |
---|---|---|
1.980 | 2000 | 1 |
2.000 | 39500 | 2 |
2.050 | 7750 | 3 |
2.100 | 5862 | 1 |
2.130 | 2958 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
EMV (ASX) Chart |